EGFR and neoplasm: Although immunotherapy combinations, for example the combination of antibodies targeting CTLA-4 and PD1, seem to benefit some patients presenting with advanced or metastatic NSCLC, tumors with EGFR mutations in general lack abundant infiltrating lymphocytes and have a relatively low tumor mutational burden [22].